AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

27,001 Shares in AbbVie Inc. $ABBV Bought by Arbor Capital Management ...

📈 Arbor Capital Management Inc. ADV bought 27,001 shares of AbbVie in Q1, valuing the new position at $5.63 million to make it its largest holding.

🏦 Norges Bank acquired a massive new stake worth approximately $5.87 billion in the fourth quarter.

📊 Wellington Management Group LLP increased its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion.

💰 Capital World Investors lifted its position by 106.3% in Q4, now owning 13.07 million shares worth $2.99 billion.

🚀 Cardano Risk Management B.V. grew its stake by 914.6% to own 5.44 million shares valued at $1.24 billion.

📉 Geode Capital Management LLC increased its position by 10.4%, holding 44.63 million shares worth $10.18 billion.

📊 Institutional ownership of AbbVie stands at 70.23% following these significant accumulation activities.

💵 AbbVie reported Q4 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.

📈 Revenue reached $15 billion for the quarter, surpassing analyst expectations of $14.72 billion and growing 12.4% year-over-year.

🎯 Analysts forecast full-year earnings of $14.39 per share for the current fiscal year.

💸 The company announced a quarterly dividend of $1.73 per share payable on August 14th with an ex-dividend date of July 15th.

📉 AbbVie reported a net margin of 5.79% and a negative return on equity of -576.45% for the quarter.

🔼 Bank of America raised its price target to $276.00 and reaffirmed a 'buy' rating on the stock.

🔼 DZ Bank upgraded AbbVie from a 'hold' to a 'strong-buy' rating in late April.

🔼 Canaccord Genuity Group lifted its price objective to $273.00 and issued a 'buy' rating.

🔼 Cantor Fitzgerald boosted its target price to $265.00 with an 'overweight' rating.

📊 The consensus analyst rating is currently 'Moderate Buy' with an average price target of $262.81.

🏥 AbbVie focuses on therapies for complex chronic conditions across immunology, oncology, neuroscience, virology, and women's health.

📅 The company was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois.

Bullish Signals
  • Arbor Capital Management Inc. ADV established a new position in AbbVie during Q1, making the stock its largest holding at 4.6% of portfolio value.
  • Norges Bank acquired a substantial new stake worth approximately $5.87 billion in the fourth quarter.
  • Wellington Management Group LLP increased its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion.
  • Capital World Investors lifted its position by 106.3% in Q4, now owning 13.07 million shares worth $2.99 billion.
  • Cardano Risk Management B.V. grew its position by 914.6% to own 5.44 million shares valued at $1.24 billion.
  • Geode Capital Management LLC increased its stake by 10.4%, holding 44.63 million shares worth $10.18 billion.
  • Institutional ownership of AbbVie stands at 70.23% following these significant accumulation activities.
  • AbbVie reported Q4 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.
  • Revenue reached $15 billion for the quarter, surpassing analyst expectations of $14.72 billion and growing 12.4% year-over-year.
  • Analysts forecast full-year earnings of $14.39 per share for the current fiscal year.
  • Bank of America raised its price target to $276.00 and reaffirmed a 'buy' rating on the stock.
  • DZ Bank upgraded AbbVie from a 'hold' to a 'strong-buy' rating in late April.
  • Canaccord Genuity Group lifted its price objective to $273.00 and issued a 'buy' rating.
  • Cantor Fitzgerald boosted its target price to $265.00 with an 'overweight' rating.
  • The consensus analyst rating is currently 'Moderate Buy' with an average price target of $262.81.
Full Analysis
Arbor Capital Management Inc. ADV established a new position in AbbVie Inc. (NYSE: ABBV) during the first quarter, purchasing 27,001 shares valued at approximately $5.63 million. This acquisition makes AbbVie the firm's largest holding, accounting for roughly 4.6% of its portfolio. Concurrently, several other major institutional investors have significantly increased their stakes in the biopharmaceutical giant. Norges Bank added a stake worth about $5.87 billion, while Wellington Management Group LLP lifted its holdings by 457.4% to own over 10.5 million shares valued at $2.44 billion. Capital World Investors and Cardano Risk Management B.V. also substantially grew their positions in the fourth quarter, with the latter increasing its stake by 914.6%. Geode Capital Management LLC further increased its ownership to nearly 44.6 million shares, worth approximately $10.18 billion. Collectively, hedge funds and institutional investors now control 70.23% of the company's outstanding stock, indicating strong continued confidence from major capital allocators. Fundamental performance remains robust as AbbVie recently reported quarterly earnings that beat analyst expectations. The company posted $2.65 per share in earnings against a consensus of $2.59, driven by revenue of $15 billion which exceeded the $14.72 billion forecast and represented a 12.4% year-over-year increase. Analysts project full-year earnings of $14.39 per share for the current fiscal year, suggesting sustained profitability despite high payout ratios. The stock has received multiple upgrades from major research firms including Bank of America, DZ Bank, Canaccord Genuity Group, and Cantor Fitzgerald, with price targets ranging from $265 to $276. The company maintains a consistent dividend policy with an upcoming payment of $1.73 per share on August 14th for shareholders of record on July 15th, offering a yield of 2.8%. These developments collectively reinforce AbbVie's status as a core holding for institutional investors.